Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04665921 · ClinicalTrials.gov registry record · Phase 1
A Study of SGN-STNV in Advanced Solid Tumors
A Phase 1 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 111
- Enrollment target
NCT04665921 is a Phase 1 study that was terminated before completion, run by Seagen. The registered enrollment target is 111 participants.
The verdict
NCT04665921, a Phase 1 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 111 participants
- Enrollment target
Study Summary
This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how well SGN-STNV works to treat solid tumors. The study will have two parts. Part A of the study will find out how much SGN-STNV should be given to patients. Part B will use the dose found in Part A to find out how safe SGN-STNV is and if it works to treat certain types of solid tumors.
Interventions
- DRUG SGN-STNV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2021-01-18 |
| Est. Completion | 2024-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04665921
The ClinicalTrials.gov registry entry for NCT04665921 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SGN-STNV is the first listed.
NCT04665921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04665921 about?
NCT04665921 is a clinical study titled "A Study of SGN-STNV in Advanced Solid Tumors". This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how well SGN-STNV works to treat solid tumor...
What is the current status of trial NCT04665921?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 111 participants. The study started on 2021-01-18. Estimated completion is 2024-03-01.
What interventions are being tested in trial NCT04665921?
The interventions under investigation include: SGN-STNV (DRUG).
Who is sponsoring clinical trial NCT04665921?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.